Zepbound for Sleep Apnea

What the SURMOUNT-OSA trial showed

SURMOUNT-OSA randomized 469 adults with moderate-to-severe OSA and obesity to tirzepatide (10 or 15 mg) or placebo for 52 weeks. Tirzepatide reduced the apnea-hypopnea index (AHI — the number of breathing interruptions per hour) by roughly 25–29 events/hour, versus about 5–6 on placebo, in people both using and not using a PAP machine. Up to about half of those on tirzepatide no longer met the threshold for OSA symptoms at a year. Much of the benefit tracks with the weight loss tirzepatide produces.

Who qualifies

The FDA indication is adults with moderate-to-severe OSA and obesity. A diagnosis typically comes from a sleep study (in-lab or home), and a clinician confirms eligibility. Zepbound is used alongside a reduced-calorie diet and increased activity, and it does not replace a sleep evaluation.

The insurance advantage of the OSA indication

This is the part many people miss: because obstructive sleep apnea is a separate FDA-approved indication — not “weight loss” — some plans will cover Zepbound for OSA when they would deny it for obesity alone. That even applies to Medicare Part D, which by law can’t cover GLP-1s for weight loss but can cover them for a qualifying non-weight-loss indication. Coverage still needs prior authorization and varies by plan — see how payers handle it in our Zepbound coverage guide.

Zepbound vs. CPAP — not either/or

Zepbound is a treatment option, not a replacement for CPAP. CPAP remains a first-line therapy, and stopping it without medical guidance can be unsafe. Many patients use both; whether CPAP can be reduced or stopped is a decision for your sleep physician, ideally after a repeat sleep study — never a self-directed change.